Filtered By:
Condition: Thrombosis
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 145 results found since Jan 2013.
Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy
We describe a case of a young healthy women suffering from acute ischemic stroke due to large vessel occlusion without cerebral venous thrombosis 8 days after vaccination and its consequences on recanalization strategy.Considering the thrombocytopenia, intravenous thrombolysis was contraindicated. She underwent mechanical thrombectomy with complete recanalization and dramatically improved clinically.
Source: Journal of Stroke and Cerebrovascular Diseases - June 24, 2021 Category: Neurology Authors: Guillaume Costentin, Ozlem Ozkul-Wermester, Aude Triquenot, V éronique Le Cam-Duchez, Nathalie Massy, Ygal Benhamou, Evelyne Massardier Tags: Case Report Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System
To assess the association of COVID-19 vaccines and non-COVID-19 vaccines with cerebral venous sinus thrombosis (CVST).
Source: Journal of Stroke and Cerebrovascular Diseases - June 16, 2021 Category: Neurology Authors: Colin Pawlowski, John Rinc ón-Hekking, Samir Awasthi, Viral Pandey, Patrick Lenehan, AJ Venkatakrishnan, Sairam Bade, John C. O'Horo, Abinash Virk, Melanie D. Swift, Amy W. Williams, Gregory J. Gores, Andrew D. Badley, John Halamka, Venky Soundararajan Source Type: research
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
AbstractReports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2, Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is incompatible with the mortality data on cardi...
Source: Journal of Pharmaceutical Policy and Practice - May 31, 2021 Category: Pharmaceuticals Source Type: research
Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine
We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. In both patients, there was no evidence of thrombocytopenia or antiplatelet antibodies, and alternative causes for cerebral venous thrombosis were found.
Source: Journal of Stroke and Cerebrovascular Diseases - May 25, 2021 Category: Neurology Authors: Leonor Dias, Ricardo Soares-dos-Reis, Jo ão Meira, Diana Ferrão, Pedro Ribeirinho Soares, Ana Pastor, Guilherme Gama, Luísa Fonseca, Vítor Fagundes, Marta Carvalho Source Type: research
Cerebral Venous Thrombosis after BNT162b2 mRNA SARS ‑CoV‑2 vaccine
We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. In both patients, there was no evidence of thrombocytopenia or antiplatelet antibodies, and alternative causes for cerebral venous thrombosis were found.
Source: Journal of Stroke and Cerebrovascular Diseases - May 25, 2021 Category: Neurology Authors: Leonor Dias, Ricardo Soares-dos-Reis, Jo ão Meira, Diana Ferrão, Pedro Ribeirinho Soares, Ana Pastor, Guilherme Gama, Luísa Fonseca, Vítor Fagundes, Marta Carvalho Source Type: research
In Response (letter 2)
We thank Drs. Siang Kow and Shahzad Hasan for their contemporary comments on our report on Cerebral Venous Sinus Thrombosis in COVID-19 Patients: A Multicenter Study and Review of Literature.1 We acknowledge our study period of CVST patients with COVID-19 covered March 1, 2020 to November 8, 2020, which preceded the COVID-19 vaccine roll-out in December 2020.
Source: Journal of Stroke and Cerebrovascular Diseases - May 25, 2021 Category: Neurology Authors: Mohamad Abdalkader, James E. Siegler, Thanh N. Nguyen Source Type: research
Guidance Issued for Managing CVST After COVID-19 Vaccination
TUESDAY, May 11, 2021 -- In a report from the American Heart Association/American Stroke Association Stroke Council Leadership, published online April 29 in Stroke, recommendations are presented for the management of cerebral venous sinus thrombosis...
Source: Drugs.com - Pharma News - May 11, 2021 Category: Pharmaceuticals Source Type: news
Cerebral venous thrombosis following COVID-19 vaccination
We appreciate the literature review by Abdalkader et al.1 to summarize the clinical epidemiology and features of cerebral venous thrombosis (CVT) in patients with coronavirus disease 2019 (COVID-19). Based on the meta-analysis performed by Baldini et al.,2 the estimated proportion of CVT cases among hospitalized patients with COVID-19 was 0.08%; therefore, it is not surprising that COVID-19 associated CVT had not been given much attention compared to the more common deep vein thrombosis and pulmonary embolism events in this patient population.
Source: Journal of Stroke and Cerebrovascular Diseases - May 10, 2021 Category: Neurology Authors: Chia Siang Kow, Syed Shahzad Hasan Tags: Letter to the Editor Source Type: research
Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine
We describe the first Danish case of presumed inflammatory and thrombotic response to vaccination with an adenoviral (ChAdOx1) vector based COVID-19 vaccine (AZD1222). The case describes a 60-year old woman, who was admitted with intractable abdominal pain seven days after receiving the vaccine. Computer Tomography (CT) of the abdomen revealed bilateral adrenal hemorrhages. On the following day she developed a massive right sided ischemic stroke and Magnetic Resonance Imaging (MRI) angiography showed occlusion of the right internal carotid artery. The ischemic area was deemed too large to offer reperfusion therapy. During ...
Source: Thrombosis and Haemostasis - April 20, 2021 Category: Hematology Authors: Rolf Ankerlund Blauenfeldt S øren Risom Kristensen Siw Leiknes Ernstsen Claudia Christina Hilt Kristensen Claus Ziegler Simonsen Anne-Mette Hvas Source Type: research
Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination
Publication date: Available online 14 April 2021Source: The LancetAuthor(s): Antonios Bayas, Martina Menacher, Monika Christ, Lars Behrens, Andreas Rank, Markus Naumann
Source: The Lancet - April 15, 2021 Category: General Medicine Source Type: research
What you should do if you’ve received the Johnson & Johnson coronavirus vaccine
Six women who had the vaccine suffered from cerebral venous sinus thrombosis, a rare form of stroke. Here’s what to know about symptoms of blood clots if you received the vaccine.
Source: Washington Post: To Your Health - April 13, 2021 Category: Consumer Health News Authors: Lenny Bernstein Source Type: news
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
